[1]
Spiro RH. Distant metastasis in adenoid cystic carcinoma of salivaryorigin. Am J Surg 1997; 01174(5): 495-98.
[2]
Ellington CL, Goodman M, Kono SA, Grist W, Wadsworth T, Chen AY. Adenoid cystic carcinoma of the head and neck: incidence and survival trends based on 1973-2007 surveillance, epidemiology and end results data. Cancer-Am Cancer Soc 2012; 15118(8): 4444-51.
[3]
Kaira K, Toyoda M, Shino M, et al. Clinicopathological significance of L-type amino acidtransporter 1 (LAT1) expression in patients with adenoid cystic carcinoma. Pathol Oncol Res 2013; 0119(4): 649-56.
[6]
Bradley PJ. Adenoid cystic carcinoma evaluation and management: progress with optimism. Curr Opin Otolaryngol 2017; 0125(2): 147-53.
[7]
Papaspyrou G, Hoch S, Rinaldo A, et al. Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: A review. Head Neck 2011; 0133(6): 905-11.
[8]
Liu XY, Liu ZJ, He H, Zhang C, Wang YL. MicroRNA-101-3psuppresses cell proliferation, invasion and enhances chemotherapeutic sensitivity in salivary gland adenoid cystic carcinoma by targeting Pim-.1. Am J Cancer Res 2015; 5(10): 3015-29.
[10]
Zhou B, Li T, Liu Y, Zhu N. Preliminary study on XAGE-1b gene and its mechanism for promoting tumor cell growth. Biomed Rep 2013; 1(4): 567-72.
[11]
Xiao C, Pan Y, Zeng X, et al. Down regulation of hypoxia inducible factor-1alpha inhibits growth, invasion and angiogenesis of human salivary adenoid cystic carcinoma cells under hypoxia. Oncol Rep 2018; 40(3): 1675-83.
[12]
Li Z, Tang P, Xu Z. Clinico-pathological significance of micro vessel density and vascular endothelial growth factor expression in adenoid cystic carcinoma of salivary glands. Chinese J Stomat 2001; 36(3): 212-4.
[13]
Kondo S, Mukudai Y, Soga D, Nishida T, Takigawa M, Shirota T. Differential expression of vascular endothelial growth factor in high- and low-metastasis cell lines of salivary gland adenoid cystic. Int J Can Res Treat 2014; 34(2): 671-7.
[14]
Ou YK, Liang J, Yang ZN, Zhao JJ. A study on the inhibition of VEGF expression in salivary gland adenoid cystic carcinoma cells via iNOS gene RNAi in vitro. J Oral Pathol Med 2015; 44(2): 153-8.
[15]
Liu X, Wu H, Huang P, Zhang F. JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways. J Oral Pathol Med 2018; 48(1): 43-51.
[17]
Wang Y, Hu J, Wang Y, et al. EGFR activation induced Snail-dependent EMT and myc-dependent PD-L1 inhuman salivary adenoid cystic carcinoma cells. Cell Cycle 2018; 17(12): 1457-70.
[19]
Hu B, Xiong Y, Ni R, et al. The down regulation of ErbB3 binding protein 1 (EBP1) is associated with poor prognosis and enhanced cell proliferation in hepatocellular carcinoma. Mol Cell Biochem 2014; 396(1-2): 175-85.
[20]
Sun J, Luo Y, Tian Z, Gu L, Xia SC, Yu Y. Expression of ERBB3binding protein 1 (EBP1) in salivary adenoid cystic carcinoma and its clinic pathological relevance. BMC Cancer 12: 499.
[21]
Qiu CW, Liu ZY, Hou K, et al. Wip1 knockout inhibits neurogenesis by affecting the Wnt/beta-catenin signaling pathway in focal cerebral ischemia in mice. Exp Neurol 2018; 309: 44-53.
[22]
Peng TS, He YH, Nie T, et al. PPM1D is prognostic marker and therapeutic target in colorectal cancer. Exp Ther Med 2014; 8(2): 430-4.
[23]
Tang YL, Liu X, Gao SY, et al. WIP1 stimulates migration and invasion of salivary adenoid cystic carcinoma by inducing MMP-9 and VEGF-C. Onco-Target 2015; 6(11): 9031-44.
[24]
Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa] B activity. Annu Rev Immunol 2000; 18: 621-63.
[25]
Xu D, Li D, Lu Z, Dong X, Wang X. Type III TGF-beta receptor inhibits cell proliferation and migration in salivary glands adenoid cystic carcinoma by suppressing NF-kappa B signaling. Oncol Rep 2016; 35(1): 267-74.
[26]
Fujioka S, Sclabas GM, Schmidt C, et al. Function of nuclear factor kappa B in pancreatic cancer metastasis. Clin Cancer Res 2003; 9(1): 346-54.
[27]
Zhang J, Peng B, Chen X. Expressions of nuclear factor kappa inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome. Clin Cancer Res 2005; 11(20): 7334-43.
[28]
Liu Z, Huang S, Zhang S, et al. Suppression of NF-kappaB activity by mutant I kappa B alpha: A molecular target for radio sensitization of adenoid cystic carcinoma. Oncol Lett 2013; 5(4): 1375-81.
[29]
Honma K, Miyata T, Ochiya T. Type I collagen gene suppresses tumor growth and invasion of malignant human glioma cells. Cancer Cell Int 2007; 7: 12.
[30]
Freitas VM, Vilas-Boas VF, Pimenta DC, et al. SIKVAV, a laminin alpha1-derived peptide, interacts with integrin’s and increases protease activity of a human salivary gland adenoid cystic carcinoma cell line through the ERK1/2 signaling pathway. Am J Pathol 2007; 171(1): 124-38.
[31]
Sun J, Yu YC, Luo YX, Tian Z. Expression of erythroblast leukemia viral oncogene homo-log 3 (ErbB-3) binding protein-1, matrix metalloproteinases, epithelial cadherin in adenoid cystic carcinoma and correlation analysis. Chinese J Stomat 2012; 47(12): 711-14.
[35]
Wang Y, Ma S, Wang W, et al. Inhibition of survivin reduces hif-1α, tgf-β1 and tfe3 in salivary adenoid cystic carcinoma. PLoS ONE 2014; 9(12): e114051.
[36]
Li J, Lee AS. Stress induction of GRP78/BiP and its role in cancer. Curr Mol 2006; 6(1): 45-54.
[37]
Kaira K, Toyoda M, Shimizu A, et al. Expression of ER stress markers (GRP78/BiP and PERK) in adenoid cystic carcinoma. Acta Otolaryngol 2016; 136(1): 1-7.
[38]
Chiarle R, Fan Y, Piva R, et al. S-phase kinase-associated protein 2 expression in non-Hodgkin lymphoma inversely correlates with p27 expression and defines cells in S phase. Am J Pathol 2002; 160(4): 1457-66.
[40]
Zhang H, Kobayashi R, Galaktionov K, Beach D. p19Skp1 andp45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase. Cell 1995; 82(6): 915-25.
[43]
Bu LL, Deng WW, Huang CF, Liu B, Zhang WF, Sun ZJ. Inhibition of STAT3 reduces proliferation and invasion in salivary gland adenoid cystic carcinoma. Am J Cancer Res 2015; 5(5): 1751-61.
[44]
Yu GT, Bu LL, Zhao YY, et al. Inhibition of mTOR reduce Stat3 and PAI related angiogenesis in salivary gland adenoid cystic carcinoma. Am J Cancer Res 2014; 4(6): 764-75.
[45]
Fan TF, Deng WW, Bu LL, Wu TF, Zhang WF, Sun ZJ. B7-H3regulates migration and invasion in salivary gland adenoid cystic carcinoma via the JAK2/STAT3 signaling pathway. Am J Transl Res 2017; 9(3): 1369-80.
[46]
Lin L, Amin R, Galliano GI, et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGFbeta signaling. Oncogene 2009; 28(7): 961-72.
[47]
Li W, Zou ST, Zhu R, Wan JM, Xu Y, Wu HR. B cell translocation1 gene inhibits cellular metastasis associated behavior in breast cancer. Mol Med Rep 2014; 9(6): 2374-80.
[48]
Stein U, Walther W, Arlt F, et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 2009; 15(1): 59-67.
[49]
Li H, Liao X, Liu Y, et al. The expression of MACC1 and its role in the proliferation and apoptosis of salivary adenoid cystic carcinoma. J Oral Pathol Med 2015; 44(10): 810-17.
[50]
Fetsch PA, Abati A, Litman T, et al. Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer Lett 2006; 235(1): 84-92.
[51]
Li W, Tamamura R, Wang B, et al. Expressions of ABCG2, CD133, and podoplanin in salivary adenoid cystic carcinoma. BioMed Res Int 2014; 2014: 1-11.
[54]
Perrone F, Da RL, Orsenigo M, et al. PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor. NeuroOncol 2009; 11(6): 725-73.
[57]
Ramer N, Wu H, Sabo E, et al. Prognostic value of quantitative p63 immunostaining in adenoid cystic carcinoma of salivary gland assessed by computerized image analysis. Cancer Am Soc 2009; 116(1): 77-83.
[58]
Ramer N, Wu H, Sabo E, et al. Prognostic value of quantitative p63 immunostaining in adenoid cystic carcinoma of salivary gland assessed by computerized image analysis. Cancer Am Soc 2010; 116(1): 77-83.
[62]
Mitani Y, Li J, Rao PH, et al. Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinic pathologic significance. Clin Cancer Res 2010; 16(19): 4722-31.
[66]
Ding LC, She L, Zheng DL, et al. Notch-4 contributes to the metastasis of salivary adenoid cystic carcinoma. Oncol Rep 2010; 24(2): 363-8.
[70]
Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta catenin signaling: diseases and therapies. Nat Rev Genet 2004; 5(9): 691-701.
[71]
Wang R, Geng N, Zhou Y, et al. Aberrant Wnt-1/beta-catenin signaling and WIF-1 deficiency are important events which promote tumor cell invasion and metastasis in salivary gland adenoid cystic carcinoma. Biomed Mater Eng 2015; 26(Suppl 1): S2145-53.
[72]
Wendt MK, Tian M, Schiemann WP. Deconstructing the mechanisms and consequences of TGF-beta-induced EMT during cancer progression. Cell Tissue Res 2012; 347(1): 85-101.
[73]
Dong L, Wang YX, Li SL, et al. TGF beta1 promotes migration and invasion of salivary adenoid cystic carcinoma. J Dent Res 2011; 90(6): 804-9.
[76]
Wang Y, Hu J, Wang Y, et al. EGFR activation induced Snaildependent EMT and myc-dependent PD-L1 inhuman salivary adenoid cystic carcinoma cells. Cell Cycle 2018; 17(12): 1457-70.
[77]
Dong L, Ge XY, Wang YX, et al. Transforming growth factor-beta and epithelial-mesenchymal transition are associated with pulmonary metastasis in adenoid cystic carcinoma. Oral Oncol 2013; 49(11): 1051-8.
[79]
Omori I, Yamaguchi H, Miyake K, Miyake N, Kitano T. D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia. Exp Hematol 2017; 52: 56-64.
[81]
Seethala RR, Barnes EL, Hunt JL. Epithelial-myoepithelial carcinoma: a review of the clinico-pathologic spectrum and immunophenotypic characteristics in 61 tumors of the salivary glands and upper aero digestive tract. Am J Surg Pathol 2007; 31(1): 44-57.
[82]
Tang YL, Fan YL, Jiang J, et al. C-kitinduces epithelialmesenchymal transition and contributes to salivary adenoid cystic cancer progression. Onco-Target 2014; 5(6): 1491-501.
[84]
Coca-Pelaz A, Rodrigo JP, Bradley PJ, et al. Adenoid cystic carcinoma of the head and neck-An update. Oral Oncol 2015; 51(7): 652-61.
[85]
Cordesmeyer R, Schliephake H, Kauffmann P, et al. Clinical prognostic factors of salivary adenoid cystic carcinoma: A single-center analysis of 61 patients. J Cranio maxillofac Sur. 2017; 45(11): 1784-87.